The association of bupropion, used for addiction to opioids and alcohol, with naltrexone, used for the treatment of depression and nicotine addiction, has been shown to reduce body weight through the action of hypothalamic nucleus arcuatus and on the dopaminergic mesolimbic system, respectively stimulating pro-opiomelanocortin (POMC) neurons and blocking the negative feedback of β-endorphins [103]. Here, POMC is linked to nicotine dependence.